Sarepta Therapeutics to Present Company Overview at the 2017 35th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced that it is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 10, 2017 at 7:30 a.m. PST (10:30 a.m. EST). Edward Kaye, Sarepta's chief executive officer, will be the presenter.

The presentation will be webcast live on the investor relations section of the Sarepta Therapeutics website at www.sarepta.com and will be archived under the events and presentations section following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates. For more information, please visit us at www.sarepta.com.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our web site at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170103005439/en/

Sarepta Therapeutics, Inc.
Media and Investors:
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]

Source: Sarepta Therapeutics, Inc.

You May Also Be Interested In

• Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
• ADSK INVESTOR ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Autodesk, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADSK
• Perk Labs Announces Closing of Non-Brokered Private Placements